Market Snapshot

BSE Sensex: 82365.77 0.28%
BSE 500: 37459.06 0.42%
BSE 200: 11679.27 0.40%
BSE 100: 26726.58 0.37%
BSE MidCap: 49065.36 0.53%
BSE SmallCap: 56021.55 0.75%
BSE BANKEX: 58311.51 0.16%
BSE IT: 43486.56 0.44%
Nifty 50: 25235.9 0.33%
Nifty 500: 23734.55 0.44%
Nifty 200: 14295.7 0.38%
Nifty 100: 26274.35 0.33%
Nifty Midcap 100: 59286.65 0.68%
Nifty Small 100: 19307.1 0.48%
Nifty IT: 42787.8 0.46%
Nifty PSU Bank: 6985.8 0.30%

News:

CRISIL reaffirms rating of Kal...
Insecticides (India) board OKs...
Adani Ports and SEZ to buy 80%...
HAL gains on inking pact with ...
Zydus Life Jarod facility rece...

Marksans Pharma Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

30 Aug 2024 | 03:59 PM

238.90

5.00 (2.14%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

111.51%

Return (1Y)

Beaten BSE Healthcare by 56.59%
More Volatile

3.12%

Standard Deviation (1Y)

Higher than BSE Healthcare by 2.29%
Not so consistent

6/12

Months

underperformed BSE Healthcare
AxisDirect View

No View

52 Week High-Low

243

News & Announcements

Marksans Pharma announces receipt of UKMHRA approval for Fluoxetine capsules
11 days ago

Marksans Pharma announces receipt of UKMHRA approval for Fluoxetine capsules

21 - Aug - 2024 12:00 AM | 11 days ago

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization from UKMHRA for the below mentioned products:
1) Fluoxetine 10mg Capsules
2) Fluoxetine 30mg Capsules
3) Fluoxetine 60mg Capsules
Powered by Capital Market - Live News
Marksans Pharma gets EIR from USFDA for Goa facility
12 days ago

Marksans Pharma gets EIR from USFDA for Goa facility

20 - Aug - 2024 12:00 AM | 12 days ago

The inspection has been classified as voluntary action indicated (VAI) and has been closed accordingly, the firm added.
Earlier, on 18 April 2024, the USFDA conducted good manufacturing practices (GMP) inspection at the company’s facility located at Verna Industrial estate, Verna, Goa, India and issued five inspectional observations in Form 483. The inspection was conducted from 9 April to 17 April 2024.
Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.
The pharma company reported 29.27% increase in consolidated net profit to Rs 88.75 crore in Q1 FY25 from Rs 68.66 crore in Q1 FY24. Revenue from operations jumped 18.12% YoY to Rs 590.62 crore in first quarter of FY25.
The scrip rose 0.36% to Rs 221.30 on the BSE.
Powered by Capital Market - Live News
Marksans Pharma's Verna unit successfully completes USFDA inspection
12 days ago

Marksans Pharma's Verna unit successfully completes USFDA inspection

20 - Aug - 2024 12:00 AM | 12 days ago

Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR) for its manufacturing facility located at Verna, Goa and the inspection has now been successfully closed by the USFDA. USFDA has determined that the inspection classification of this facility is “Voluntary Action Indicated” (VAI).
Powered by Capital Market - Live News
Marksans Pharma to convene AGM
12 days ago

Marksans Pharma to convene AGM

20 - Aug - 2024 12:00 AM | 12 days ago

Marksans Pharma announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Marksans Pharma Ltd is trading very close to its All time High
Marksans Pharma Ltd is trading very close to its 52 Week High
FII shareholding in Marksans Pharma Ltd has increased by 64.49% since past 3 Months
MF shareholding in Marksans Pharma Ltd has decreased by -33.43% since past 3 Months

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

General Notifications

My Notifications

Research Notifications

Marksans Pharma Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

238.90 5.00 (2.14%)

News & Announcements

Price vs Volume

Stock Trivia

Marksans Pharma Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

238.90

5.00 (2.14%)